Formulations of dengue virus vaccine compositions
AssigneeMerck Sharp & Dohme Corp.
InventorsMichael S. Ryan, Sherrie-Ann P. Martin, Jeffrey Thomas Blue, Heidi Joanne Pixley, Erin J. Green-Trexler, Lynne Ann Isopi
Life of this patent
Estimating the term…
Abstract
The present invention relates to formulations of dengue virus vaccine comprising at least one live, attenuated dengue virus or live, attenuated chimeric flavivirus, a buffer, a sugar, a cellulose derivative, a glycol or sugar alcohol, optionally an alkali or alkaline salt and an amino acid; and formulations of dengue virus vaccine comprising at least one live, attenuated dengue virus or live, attenuated chimeric flavivirus, a buffer, a sugar of at least 150 mg/ml, a carrier, and optionally an alkali or alkaline salt and an amino acid.
Claims8
A formulation that comprises the following components:
- a) a live attenuated tetravalent dengue vaccine comprising i) about 100-10,000,000 pfu/ml rDEN1Δ30 virus, ii) about 100-10,000,000 pfu/ml rDEN2/4Δ30 virus, iii) about 100-10,000,000 pfu/ml rDEN3Δ30/31 virus, and iv) about 100-10,000,000 pfu/ml rDEN4Δ30 virus,
- b) about 11 mM potassium phosphate buffer at a pH of about 7.0-8.0,
- c) about 90 mg/ml sucrose,
- d) about 5 mg/ml propylene glycol,
- e) about 5 mg/ml sodium carboxymethylcellulose,
- f) about 50 mM NaCl, and
- g) about 25 mM Leu.
A formulation that comprises the following components:
- a) a live attenuated tetravalent dengue vaccine comprising i) 100-10,000,000 pfu/ml rDEN1Δ30 virus, ii) 100-10,000,000 pfu/ml rDEN2/4Δ30 virus, iii) 100-10,000,000 pfu/ml rDEN3Δ30/31 virus, and iv) 100-10,000,000 pfu/ml rDEN4Δ30 virus,
- b) 11 mM potassium phosphate buffer at a pH of 7.0-8.0,
- c) 90 mg/ml sucrose,
- d) 5 mg/ml propylene glycol,
- e) 5 mg/ml sodium carboxymethylcellulose,
- f) 50 mM NaCl, and
- g) 25 mM Leu.
Dependencies are inferred from the claim text.